Med. Pro Praxi 2008; 5(7)

Slovo úvodem

Published: December 19, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slovo úvodem. Med. praxi. 2008;5(7):.

Vážení čtenáři,

na letošní prázdniny jsme pro vás místo obvyklého dvojčísla časopisu Medicína pro praxi připravili speciální brožurku Zimní období v ordinaci praktického lékaře.

Poskytne stručný a rychlý přehled nejčastějších onemocnění, s nimiž do vašich ambulancí přicházejí pacienti v chladnějších obdobích roku. Seznámí vás s jejich diagnostikou a léčbou na základě doporučených postupů. Nechybějí ani tolik důležité informace týkající se prevence očkováním.

Doufáme, že tato novinka bude vítaným zpestřením a usnadní vám přístup k aktuálním informacím. Brožurka je k dispozici fe formátu PDF.

Redakce

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. Nature Rev Microbiol 2007; 5: 529-539. Go to original source... Go to PubMed...
    2. Antiviral drugs. Wikipedia, the free encyklopedia (http://en.wikipedia.org/wiki/Antiviral_drug).
    3. Barber DI, Wherry EJ, Masopust D et al. Restoring function of exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687. Go to original source... Go to PubMed...
    4. Barclay L. Guidelines updated for varicella prevention in children, teens, adults. MMWR Morb Mortal Wly 2007; 56: 1-40.
    5. Bartůňková J. Primární a sekundární imunodeficity. V Imunologie ´98, M. Nouza a K. Nouza (Eds), Praha: Galén 1999; 19-35.
    6. Busca A, de Fabritiis P, Ghisetti V et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis. 2007; 9(2): 102-107. Go to original source... Go to PubMed...
    7. Bystroň J. Thymostimulin (TP-1 Serono) - současné možnosti léčebného použití a dávkování. Fórum imunologie 1994; 2: 101-104.
    8. Bystroň J. Perorální bakteriální imunomodulátory a medicína založená na důkazech. Alergie 2003; 5(4): 284-290.
    9. Casadevall A, Scharff MD. Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21: 150-161. Go to original source... Go to PubMed...
    10. Kawai T, Akira S. Innate immune recognition of viral infection. Nature Immunology 2006; 7: 131-137. Go to original source... Go to PubMed...
    11. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; Mar 29, 35: 1338-1343. Go to original source... Go to PubMed...
    12. Mils J. Virové infekce. In: Základní a klinická imunologie. DP Sites, AI Terr (Eds), Victoria publishing 1991; 581-590.
    13. Nouza K, John C. Zdraví v novém miléniu - Imunologie. Ve Sborníku ze semináře v PSP ČR, 2001; 26(11): 15-22.
    14. Nouza K, Nouza M. Využití pasivní imunoterapie v onkologii a imunologii. Lek Listy 2002; 34: 19-21.
    15. Nouza K, Nouza M. Léčebné možnosti aplikace imunomodulátorů. Lek Listy 2000; 34: 6-7.
    16. Nouza K, Nouza M. Nachlazení nemusí být bezvýznamné. Lek listy 2002; 34: 10-12.
    17. Nouza M. Interakce parazita s hostitelem. Lek Listy 2000; 34: 1-2.
    18. Nouza M. Nejrozšířenějším lidským virem ve světě je CMV. Lek Listy 2000; 34, 258: 2.
    19. Nouza M. Role viru Epsteina a Barrové v soužití s člověkem. Lek Listy 2 000; 34: 3.
    20. Okano M, Gross TG. A review of Epstein-Barr virus infection in patients with immunodeficiency disorders. J Am J Med Assc, 2000; 319 (6): 392-396. Go to original source... Go to PubMed...
    21. Pekárek J. Léčebné využití přípravku Immodin Sevac (Transfer faktor) u některých poruch buněčné imunity. Praktický lékař 1993; 73: 148-150.
    22. Pitkäranta A, Hayded FG. What' s New With Common Colds? Pathogenesis and Diagnosis. Infect Med 1998; 1: 50-59 and 1998; 2: 117-226.
    23. Pružinec P. Isoprinosine. Klinická imunológia a alergológia 1995; 5: 21-24.
    24. Současné možnosti imunomodulační léčby v praxi. Farmakoterapeutické informace 2005; 1: 1-2.
    25. Sedláček D. Herpetické viry a jejich význam v patogenezi lidských onemocnění. Lek Listy 2001; 35: 20-22.
    26. Sedláček D. Antivirotika pro systémové použití. Lek Listy 2002; 8: 23-25.
    27. Štruncová V. Klíšťová encefalitida. Lek Listy 2001; 35: 16-19.
    28. Vonka V, Hamšíková E. Vakcína proti lidským papillomavirům: co jí předcházelo, jaká je a co nás čeká v budoucnosti. Vakcinologie 2007; 1(1): 6-16.
    29. Zeitlin L. Cone R. A: Emerging Infectious Diseases 1999; 5: 1-13. Go to original source...
    30. ##
    31. Chandra RK. Influence of multinutrient supplement on immune responses and infection-related illness in 50-65 year old individuals. Nutrition Research 2002; 22: 5-11. Go to original source...
    32. ##
    33. Cram P, Blitz SG, Monto A et all. Influenza. Cost of illness and consideration in the economic evaluations of new and emerging therapies. Pharmacoeconomics. 2001; 19(3): 223-230. Go to original source... Go to PubMed...
    34. Potter CW. A history of influenza. Journal of Applied Microbiology 2001; 91: 572-579. Go to original source... Go to PubMed...
    35. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patiens. Lancet, 1933: 66-68. Go to original source...
    36. Smith W, Andrewes CH, Start-Harris CH. The immunization of human volunterees. Special Rep Ser Med Res Council, 1938, 228: 137-144.
    37. ##
    38. Beran J, Havlík J. Chřipka. Průvodce ošetřujícího lékaře. Praha: Maxdorf 2005; 80-83.
    39. Beran J, Havlík J, Vonka V. Očkování. Praha: Galen 2005; 99-104.
    40. Kolektiv autorů. Manuál prevence v lékařské praxi. Praha: Fortuna 1996; 59-60.
    41. Petráš M, Domorázková E, Petrýdesová A. Manuál očkování: 92-100.
    42. Registr hlášení ARI, HS. SZÚ Praha 2. vyd. 1998.
    43. www.mzcr.cz
    44. ##
    45. Čáp P, Vondra V. Kašel. Praha: Vltavín, 2000.
    46. Irwin RS et al. Chronic cought: the spectrum and frequency. Am. Rev. Resp. Dis. 1990; 141: 640-647. Go to original source... Go to PubMed...
    47. Kolek V. Chronický kašel. Praha 2000.
    48. ##
    49. Aruoma OI, Halliwell B, Hoey BM. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. Free Rad. Biol. Mes. 1989; 6: 593. Go to original source... Go to PubMed...
    50. Braga PC, Dal Sasso M, Sala MT, et al. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittel Forschung Drug Research 1999; 494: 344-349.
    51. Biagi GL, Fregnan GB, Gazzani G. Erdosteine protection from cigarette smoke-induced loss of ?-1-antitrypsin activity in rat lungs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989; 27: 235-237.
    52. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003; 22: 912-919. Go to original source... Go to PubMed...
    53. Celli BR, MacNee W, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23: 932-946. Go to original source... Go to PubMed...
    54. Ciaccia A, Papi A, Tschirky B, et al. Protection of erdosteine on smoke-induced peripheral neutrophil dysfunction both in healthy and in bronchitic smokers. Fundam. Clin. Pharmacol. 1992; 6: 375-379. Go to original source... Go to PubMed...
    55. Decramer M, Rutten-van Mölken M, Dekherijeen PNR, et al. Effect of N-acetylcystein on outcomes in chronic obstrutive pulmonary disease (Bronchitis Randomized on N-acetylcystein Cost-Utility Study, BRONCUS): a randomised placebocontrolled trial. Lancet 2005; 365: 1552-1560. Go to original source... Go to PubMed...
    56. Dal Sasso M, Bovio C, Culici M, et al. The SH-metabolite I of erdostein, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils. Drugs. Exp. Clin. 2002; 28: 147-154.
    57. Dal Sasso M, Culici M, Guffanti EE, et al. A combination of budenoside and the SH-metabolite I of erdostein acts synergistically in reducing chemiluminiscence dutiny human neutrophil respiratory burst. Pharmacol. 2005; 74: 127-134. Go to original source... Go to PubMed...
    58. Dal Negro RW, Visconti M, Micheletto C, et al. Erdostein 900 mg/day affects substancially blood ROS,e-NO and some chemotactic cytokines from bronchial secretions of current smokers. A pilot study. ATS 2005 Abstr. Book.
    59. Donnini M, Luisetti M, Diomede L, et al. Ambroxol reduces paraguat toxicity in the rat. In: Wichert P, von Muller B, eds. Basic Research on Lung Surfactant Progress in Respiratory Research. Karger, Basel, 1990; 329-332. Go to original source...
    60. Fioretti M, Bandiera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med. Praxis. 1991; 12: 219-222.
    61. Gene R, et al. Influence of ambroxol on amoxicillin levels in broncho-alveolar lavage fluid. Arzneim.-Forsch./Drug. Res. 1987; 37: 967-968.
    62. Gerrits CMJM, Herings RMC, Leufkens HGM, et al. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003; 21: 795-798. Go to original source... Go to PubMed...
    63. Grande JM, Snell NJ. Activity of bromhexine and ambroxol semi-synthetic derivatives of vasicine from the Indian shrub Adhatoda vasica against Mycobacterium tuberculosis in vitro. J. Ethopharmacol 1996; 50: 49-53. Go to original source...
    64. Grandjean EM, Berthet P, Ruffman R, et al. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebocontrolled clinical trials. Clin. Ther. 2000; 22: 209-212. Go to original source... Go to PubMed...
    65. Hayashi K, Hosoe H, Kaise T. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice. J. Pharm. Pharmacol. 2000; 52: 1411-1413. Go to original source... Go to PubMed...
    66. Hosoe H, Kaise T, Ohmori K. Effects on the Reactive Oxygen Species of Erdosteine and its Metabolite in vitro. Arzneim.-Forsch. Drug Res. 2002; 52: 435-440. Go to original source...
    67. Irwin RS, Curley FL, Bennett FM. Appropriate use of antitussives and protussives: a practical review. Drugs. 1993; 46: 80-91. Go to original source... Go to PubMed...
    68. Kastelik JA, Aziz I, Ojoo JC, et al. Investigation and management of chronic cough using a probability-based algorithm. Eur Respir J. 2005; 25: 235-243. Go to original source... Go to PubMed...
    69. Kolek V, Engel G. Ambroxol : Známá látka s novým spektrem klinického využití. Zpravodaj klinické farmakologie a farmacie 1997; 11: 25-29.
    70. Kolek V. Chronický kašel. Příčiny, diagnostika, léčba. Praha, Vltavín, 2002; 72 s.
    71. Marchioni CF, Moretii M, Muratory M, et al. Effects of erdosteine on sputum biochemical and rheologic properties: Pharmacokinetics in chronic obstructive pulmonary disease. Lung 1990; 68: 285-293. Go to original source... Go to PubMed...
    72. Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda G, and Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharm. and Therap. 1995; 33: 612-618.
    73. Moretti M, Bottrighi P, Falladi R, et al. The effect of longterm treatment with erdostein on chronic obstructive pulmonary disease: The EQALIFE study. Drugs Explt. Clin. Res. 2004; 30: 143-152.
    74. Miyake K, Kaise T, Hosoe H. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflammation Res. 1999; 48: 205-210. Go to original source... Go to PubMed...
    75. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical quideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl I).
    76. Olivieri D, Del Donno M, Vasalini A, et al. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respiration 1991; 58: 91-94. Go to original source... Go to PubMed...
    77. Poole PJ, Black PN. Mucolytic for chronic bronchitis or chronic obstructive pulmonary disease (Cochrane Methodology Review). In: The Cochrane Library, Issue 4, John Wiley&Sons, Ltd., Chichester, 2003; 121-130. Go to original source...
    78. Repine JE, Bast A, Lankhorst I. and the Oxidative Stress Study Group: Oxidative stress in COPD. Am. J. Respir. Crit. Care Med. 1997; 156: 341-357. Go to original source... Go to PubMed...
    79. Rubin BK. An In Vitro Comparison of the Mucoactive Properties of Guaifenesin, Iodinated Glycerol, Surfactant, and Albuterol. CHEST 1999; 116: 195-200. Go to original source... Go to PubMed...
    80. Stey C, Steurer J, Bachmann S. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000; 16: 253-262. Go to original source... Go to PubMed...
    81. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81. Go to original source... Go to PubMed...
    82. Vagliasindi M, Fregnan GB. Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989; 27: 238-241.
    83. www.goldcopd.com: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
    84. Zanasi A, Menadini A. Erdostein versus N-acetylcystein in the treatment of exacerbation of chronic bronchopneumopathies. Med. Praxis 1991; 12: 207-217.
    85. ##
    86. Autorský kolektiv. Zásady diagnostiky a racionální terapie infekcí horních cest dýchacích. Mediforum 2001.
    87. Autorský kolektiv. Pharmindex Brevíř, Medical Tribune 2006.
    88. Holcát M. Léčiva používaná k terapii nemocí nosu a vedlejších nosních dutin. Remedia, Compendium, třetí vydání, 1999: Panax Co, spol. s.r.o.: 584-594.
    89. Honzíková M, a kol. Systémová enzymoterapie v komplexní léčbě recidivujících zánětů dýchacích cest u dětí - postregistrační retrospektivní multicentrické hodnocení. Čes. slov. Pediatr. 2004; 59(10): 513-521.
    90. Hybášek I. Záněty nosu a nosních dutin. Ušní, nosní a krční lékařství. Praha: Galén, 1999: 84-89.
    91. Klozar J, et al. Záněty nosu a vedlejších dutin nosních. Speciální otorinolaryngologie. Praha: Galén, 2005: 32-38.
    92. Lejska V. Rýmy u dětí. Kompendium ORL dětského věku. Praha: Grada, 1995: 140-149.
    93. ##
    94. Bartoníčková K, Bébrová E, Beneš J, Čížek J, Dostál V, Galský J, Horáčková M, Chmelík V, Jindrák V, Karen I, Kolář M, Kolská M, Kolský A, Marek J, Marešová V, Matoušková M, Nýč O, Urbášková P. Doporučený postup pro antibiotickou léčbu komunitních infekcí ledvin a močových cest v primární péči. Praktický lékař 2006; 86(8): 429-438 (www.cls.cz/dp/2006/dpimc.doc).
    95. Blechová Z. Časté komunitní infekce dětského věku a jejich léčba. Pediatr. pro Praxi. 2005; 6(2): 71-75.
    96. Cunha BA. Penicillin resistance in pneumococcal pneumonia. Postgrad. Med. 2003; 113(1): 42-54. Go to original source... Go to PubMed...
    97. Čižman M, Pokorn M, Seme K et al. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J. Antimicrobial. Chemother. 2001; 47: 475-477. Go to original source... Go to PubMed...
    98. Hoza J, Jindrák V, Marešová V, Nyč O, Sechser T, Suchopár J, Švihovec J, Urbášková P. Konsensus používání antibiotik I. Penicilinová antibiotika. Praktický lékař 2002; 82(5): 251-261 (www.cls.cz).
    99. Jindrák V, Bébrová E. Mikrobiologické podklady pro léčbu antibiotiky v ambulantní praxi. Klin. mikrob. inf. lék. 2000; 6(9-10): 290-293.
    100. Jindrák V, Henyšová J, Vaniš V, Urbášková P, Litoš P. Rezistence Streptococcus pyogenes k erytromycinu jako regionální problém. Klin. mikrobiol. inf. lék., 1999;5: 237-243.
    101. Marešová V. Clarithromycin. Remedia 1995; 5(4): 184-191.
    102. Marešová V, Urbášková P. Phnenoxymethylpenicillinum (penicilin V). Remedia 2005; 15(3): 221-226.
    103. Marešová V. Spiramycin. Remedia 2006; 16(1): 37-45.
    104. Marešová V. Doxycyklin. Remedia 1996; 6(5): 27-283. Go to original source...
    105. Micromedex (databáze léků). 1/2006-02-05.
    106. Nelson JD, Bradley JS. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. Lippincott Williams&Wilkins, USA, 2006.
    107. Příborský J. Makrolidy. Praha, Maxdorf: 2001.
    108. Příborský J. Cefalosporiny. Praha, Maxdorf: 1999.
    109. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. New England J. Med. 1997; 337: 441-446. Go to original source... Go to PubMed...
    110. Štika, L. Spotřeba antimikrobiálních léčiv a její vliv na rezistenci mikroorganizmů. Klin. mikrobiol. inf. lék., 2001; 10: 66-71.
    111. Urbášková P. Trendy rezistence na antibiotika u některých původců komunitních infekcí v ČR. Pediatr. pro Praxi 2000; 1(3): 105-107.
    112. Urbášková P, Jakubů V, Žemličková H a účastníci CZEARSS. EARSS v České republice: Surveillance antibiotické rezistence invazivních izolátů Streptococcus pneumoniae, Staphylococcus aureus, E. coli, Enterococcus faecalis a E. faecium. Zprávy Centra epidemiologie a mikrobiologie, 2001; 10: 310-315 (http://www.szu.cz/cem/zprávy/default.htm).
    113. Urbášková P, Jindrák V, Marešová V. Antibiotická rezistence u hlavních původců bakteriálních infekcí v ČR. Lege Artis. 2001; 1(9): 5-7.
    114. Urbášková P, Marešová V, Jindrák V, Nyč O, Suchopár J, Sechser T, Hoza J, Karen I, Švihovec J. Konsenzus používání antibiotik II. Makrolidová antibiotika. Prakt. Lék. 2003; 83(10): 563-571 (www.cls.cz/dp/2003/ATB). Go to original source...
    115. WHO Model Prescribing Information: Drugs used in bacterial infections. WHO Geneva, 2001.
    116. ##
    117. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-1213. Go to original source... Go to PubMed...
    118. Andre FE. Summary of safety and efficacy data on a yeastderived hepatitis B vaccine. Am J Med 1989; 87(Suppl 3A): 39-45. Go to original source... Go to PubMed...
    119. Aristegui J, Garrate E, Gonzales A et al. A new tetravalent vaccine containing diphteria and tetanus toxoids, whole-cell B. pertussis and a recombinant hepatitis B surface antigen administere at 2, 4 and 6 months of age. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); (Poster H137), Oct 4-7, Orlando, USA, 1994.
    120. Armstrong ME, Giesa PA, Davide JP et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA, from the live attenuated virus strain CR326F. J Hepatol 1993; 18(Suppl 2): S20-S26. Go to original source... Go to PubMed...
    121. Balcarek KB, Bagley MR, Pass RF, Schiff ER, Krause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995; 171(Suppl 1): S70-S72. Go to original source... Go to PubMed...
    122. Barbara Watson, David J. West, Andrew Chilkatowsky, Sharon Piercy, Virginia A. Ioli, Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine, Vaccine 19 (2001) 3164-3168. Go to original source... Go to PubMed...
    123. Bock HL, Kruppenbacher J, Sänger R et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996; 156: 2226-2231. Go to original source...
    124. Bruguera M, Cremades M, Salinas R et al. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14: 27-30. Go to original source... Go to PubMed...
    125. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(suppl 1): S44-S49. Go to original source... Go to PubMed...
    126. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA-genes are involved. Tissue Antigens.
    127. Emini EA, Eliis RW, Miller WJ et al. Production and immunologic analysis of recombinant hepatitis B vaccine. J Infect 1986; 13(suppl A): 3-9. Go to original source... Go to PubMed...
    128. Flehming B, Heinricy U, Pfisterer M. Prospects for a hepatitis A virus vaccine. Prog Med Virol 1990; 37: 56-71.
    129. Flehming B, Mauler RF, Noll G et al. Viral Hepatitis and Liver Disease. New York, Alan R Liss, 1988; pp.87-90.
    130. Flehming B, Vallbracht A, Wuster G. Hepatitis A in cell culture. 3. Propagation of hepatitis virus in human embryo cells and human embryo fibroblast strains. Med Microbiol Immunol 1981; 170: 83-89. Go to original source... Go to PubMed...
    131. Gluck R, Mischler R, Brantschen S et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J clin Invest 1992; 90: 2491-2495. Go to original source... Go to PubMed...
    132. Gust ID, Lehmann NI, Crowe S et al. The origin of the HM175 strain of hepatitis A virus. J Infect Dis 1985; 151: 365-367. Go to original source... Go to PubMed...
    133. Hadler SC, Judson FN, O'Malley PM et al. Studies of hepatitis B vaccine in homosexual men. In Coursaget P, Tong MJ (eds.), Progress in Hepatitis B Immunization. Paris, John Libby Eurotest. 1990; 165-175.
    134. Harries AD, Clark M, Beeching NJ et al. Early anti-HBs antibody response o accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect 1991; 23(3): 251-254. Go to original source... Go to PubMed...
    135. Heinricy U, Stierhof ZD, Pfisterer M, Flehming B. Properties of a hepatitis A virus candidate vaccine strain. J Gen Virol 1987; 68: 2487-2493. Go to original source... Go to PubMed...
    136. Hess G, Hingst V, Cseke J et al. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol Infect Dis 1992; 11: 334-340. Go to original source... Go to PubMed...
    137. Horng YC, Chang MH, Lee CY, Safary A, Andre FE, Chen DS. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993; 12: 359-362. Go to original source... Go to PubMed...
    138. Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis.
    139. Chiaramonte M, Majori S, Ngatchu T et al. Two difference dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine 1996; 14: 135-137. Go to original source... Go to PubMed...
    140. Iwarson S. New approaches to hepatitis A and B vaccines. APMIS 1995; 103: 321-326. Go to original source... Go to PubMed...
    141. Keet IPM, van-Doorum G, Safary A et al. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992; 6: 509-510. Go to original source... Go to PubMed...
    142. Lau Y-L, Tam AYC, Ng KW et al. Response of preterm infants to hepatitis B vaccine. J Pediatr 1992; 121: 962-965. Go to original source... Go to PubMed...
    143. Laukamm-Josten U, von Laer G, Feldmeier H et al. Active immunization against hepatitis B: immunogenicity of a recombinantn DNA vaccine in females, heterosexual and homosexual males. Postgrad Med J 1987; 63(suppl 2): 143-146.
    144. Lemon SM, Binn LN. Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983; 148: 1033-1039. Go to original source... Go to PubMed...
    145. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204. Go to original source... Go to PubMed...
    146. Lemon SM. Hepatitis A virus: Current concepts of the molecular virology, immunology and approaches to vaccine development. Rev Med Virol 1992; 2: 73-87. Go to original source...
    147. Nalin DR, Kuter BJ, Brown L et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adults populations: an overview. J Hepatol 1993; 18(suppl 2): S51-S55. Go to original source... Go to PubMed...
    148. Palmovic D, Crnjakovic-Palmovic J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol 1994; 10: 541-547. Go to original source... Go to PubMed...
    149. Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 1992; 10 (suppl 1): S99-S101. Go to original source... Go to PubMed...
    150. Piazza M, Safary A, Vegnente A et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 1999; 17: 585-588. Go to original source... Go to PubMed...
    151. Pietro Dentico, Pietro Crovari, Piero Luigi Lai, Franca Ponzio, Assad Safary, Anna Pellegrino, Francois Meurice, Alberta Di Pasquale, Nadia Tornieporth, Anna Volpe, Giancarlo Icardi, Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres, Vaccine 20 (2002) 3725-3730. Go to original source... Go to PubMed...
    152. Poovorawan Y, Theamboonlers A, Sanpavat S et al. Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. Asian Pac J Allergy Immunol 1999; 17: 113-120. Go to PubMed...
    153. Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979; 160: 213-221. Go to original source... Go to PubMed...
    154. Shapiro CN, Letson GW, Kuehn D et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants (Abstract H61). In: 1995 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: American Society for Microbiology, 1995; 190.
    155. Sitrin RD, Wampler DE, Ellis RW. Survey of licensed hepatitis B vaccines and their production processes. In Elis RW (ed). Hepatitis B Vaccines in Clincial Practices. New Yourk, Marcel Dekker 1993; pp. 83-101.
    156. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990; 8(suppl): S69-S73. Go to original source... Go to PubMed...
    157. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-841. Go to original source... Go to PubMed...
    158. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44: 446-451. Go to original source... Go to PubMed...
    159. Van Herck K, Van Damme P, Thoelen S. A high potency inactivated hepatitis A vaccine: long term follow-up (Abstract A02). final program/book of abstracts. 6th Conference of the International Society of Travel Medicine. Stone Mountain, GA: International Society of Travel Medicine, 1999. Go to original source...
    160. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J Infect Dis 1997; 175: 674-677. Go to original source... Go to PubMed...
    161. Wainwright RB, McMahon BJ, Bulkow LR et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Askimo population. JAMA 1989; 261: 2362-2366. Go to original source...
    162. Wang LY, Lin HH, Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago, Vaccine. 2007; Aug 1. Go to original source... Go to PubMed...
    163. Watson B, West DJ, Chilkatowsky A, Piercy S, Loli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine; Vaccine 19(2001): 3164-3168. Go to original source... Go to PubMed...
    164. WHO VHPB Hepatitis B as an occupational hazard - European Occupational Health Series N'8 1994: 1-64.
    165. Wiedermann G, Kondi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Tropica 1998; 69: 121-125. Go to original source... Go to PubMed...
    166. Wiedermann G, Kundi M, Ambrosch F et al. Inactivated hepatitis A vaccine: Long term antibody persistence. Vaccine 1997; 15: 612-615. Go to original source... Go to PubMed...
    167. Wilkinson SE, Morath M, Bennett DL et al. Accelerated schedule of hepatitis B vaccination in high-risk youth. J Paediatr Child Health 1996; 32: 60-62. Go to original source... Go to PubMed...
    168. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of the clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13(Suppl A): 39-45. Go to original source... Go to PubMed...
    169. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366: 1379-1384. Go to original source... Go to PubMed...
    170. Zuckerman JN, Van Damme P, Van Herck K, Löscher T. Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide; Travel Med Infect Dis 2003; 1: 219-226, 14. 5. 2004. Go to original source... Go to PubMed...
    171. ##
    172. Abramowits W. A clinician paradigm in the tratment of atopic dermatitis. Am Acad Dermatol 2005; 53: 70-76. Go to original source... Go to PubMed...
    173. Benáková N. Atopická dermatitida - status quo 2004. Alergie 2005, 1: 26-32.
    174. Benáková N. Ekzémy a dermatitidy. Praha: Maxdorf, 2006: 125 s.
    175. Benáková N. Léčba atopické dermatitidy/ekzému u dospělých. Interní Med. 2007; 5: 240-246.
    176. Čapková Š. Současné možnosti léčby atopické dermatitidy v dětském věku a poučení rodičů. Referátový výběr z dermatovenerologie 2004; 46/S1: 5-12.
    177. Čapková Š. Atopická dermatitida - narůstající problém v dermatologické a pediatrické praxi. In: Kolektiv autorů: Dermatovenerologie, dětská dermatologie a korektivní dermatologie 2006/2007. Praha: Triton, 2006: 179-193.
    178. Holobradá M. Komplexná liečba atopickej dermatitidy. Derma 2006; 4: 11-15.
    179. Christophers E, Folster-Hostz R. Atopic versus infantile eczema. J Am Acad Dermatol 2001; 45: 4-6. Go to original source... Go to PubMed...
    180. Klubal R (koordinátor) et al. Workshop on atopic dermatitis. Praha 26.-28. 4. 2006.
    181. Klubal R (koordinátor) et al. Workshop on atopic dermatitis. Praha 25.-27. 5. 2007.
    182. Machovcová A. Péče kůži v dětském věku. Příloha Pediatrie pro praxi 2006; 7: 50.
    183. Mohrenschlager M, Darsow U, Schnopp C, Ring J. Atopic eczema: what is new? JEADV 2006; 20: 503-511. Go to original source... Go to PubMed...
    184. Olesen AB. Atopic dermatitis - has the epidemic stopped or just begun? In: EADV Congress news 2006; 4.
    185. Polášková S. Léčba atopického ekzému. Practicus 2006; 1: 404-406.
    186. Sandilandis A, et al. Prevalent and rare mutations in gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 2006; 126: 1770-1775. Go to original source... Go to PubMed...
    187. Schmiedbergerová R. Eczema atopicum. Pediatrie pro praxi 2005; 4: 145-150.
    188. Thestrup-Pedersen K. Atopic eczema - new insights in definition, diagnostics and disease management. Acta Derm Venereol 2005; Suppl. 215: 7-48.
    189. Záhejský J. Zevní dermatologická terapie a kosmetika. Praha: Grada, 2006.
    190. Kolektiv autorů. Atopic dermatitis: current approaches and future treatment options. Dermatology News 2007; 9: 1-4.
    191. Guidelines Issued for treating atopic eczema in children. Medscape Medical News, 28 april 2008. www.medscape.com.
    192. ##
    193. Fuchs. Alergie číhá v jídle a pití. Adéla 2005: 189 s.
    194. Čapková Š, Špičák V, Vosmík F. Atopický ekzém. Praha: Makropulos 1997, reedice 2005: 138 s.
    195. Benáková N. Atopická dermatitida. Brožura pro pacienty. Vydáno za podpory Schering-Plough 2003.
    196. Čapková Š. Atopická dermatitida. Brožura pro pacienty. Vydáno za podpory Novartis 2005.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.